ResMed’s New AirCurve™ 11 Bilevel Devices Enable Healthcare Providers to Make Informed Decisions about Care, Deliver Personalized Support, and Drive Positive Therapy Outcomes for Patients with Sleep Apnea
12 Février 2024 - 10:16PM
ResMed (NYSE: RMD, ASX: RMD) launched today its AirCurve 11 series
devices, the company’s newest bilevel devices that use two levels
of support, inspiratory positive airway pressure (IPAP) and
expiratory positive airway pressure (EPAP), combined with digital
technology to make it easier for healthcare providers to treat
sleep apnea and to help patients start and stay on therapy.
AirCurve 11 devices are built on ResMed’s market-leading AirSense
11 platform and enhance the suite of offerings available for
healthcare providers and clinicians when determining the best care
for sleep apnea patients.
Addressing the challenges that some patients have adapting to
CPAP therapy, the AirCurve 11 VAuto is a bilevel PAP device
designed to improve comfort and help compliance by providing a
higher pressure during inhalation and a lower pressure during
exhalation. This design allows the device to align more closely
with the patient’s natural breathing pattern.
The AirCurve11 ASV1, ResMed’s new adaptive servo-ventilation
(ASV) device, makes therapy feel like the patient’s own breath –
which is critical for patients who present with central sleep
apnea, obstructive sleep apnea, mixed apneas or periodic breathing.
These patients often find that standard therapies are often unable
to fully normalize their breathing. The ASVAuto algorithm tracks 13
points on every breath cycle 50 times per second, using each
patient’s unique minute ventilation target and respiratory rate to
deliver therapy that stabilizes ventilation. Continuously
monitoring the shape of the patient’s breath informs the algorithm
at what points trigger and cycle are occurring, and the length of
inspiration.
“Patient care is our top priority, and that includes their
comfort and compliance with PAP therapy,” said ResMed Chief Medical
Officer Carlos M. Nunez, M.D. “We’ve seen patient compliance
improve from 70% to 87%2 through the use of coaching features and
the ability to track and view their nightly sleep data via MyAir™
and AirView™, so we’ve incorporated these digital health
applications into the new AirCurve11 series to enable maximum
comfort and support throughout the therapy experience.”
Delivering next-level support for patients and providers, the
AirCurve11 series has been designed with a powerful combination of
features and settings, including:
- Integrated cellular
and bluetooth communication enables secure and automated data
transmission to the cloud for access in AirView and myAir.
- Integrated heated
humidifier can be automatically controlled through the Climate
Control feature or manually set by the user.
- Over-the-Air updates
delivers software and new digital features directly to the
device.
- myAir3, a patient
engagement app that tracks sleep and therapy progress with a daily
sleep score, now with support for bilevel patients.
- AirView, a secure,
cloud-based system that helps providers monitor and manage
patients’ therapy remotely, enabling an informed pathway to optimal
care.
- Personal Therapy
Assistant via myAir, which offers interactive voice-guided
instructions and videos to help guide patients through equipment
setup.
- Care Check-In
periodically prompts patients with questions specific to bilevel
therapy goals.
“Our approach to product development is predicated on always
doing what is in the best interest of patients,” said Chief Product
Officer Justin Leong. "This culture of customer-centricity fuels
our passion for delivering products like the AirCurve 11 that
empower people with the ability to better care for their sleep
apnea from the comfort of their own homes.”
AirCurve 11 is available in the U.S., with other countries to
follow, and is compatible with all ResMed masks. To learn more
about AirCurve 11, visit https://resmed.com/AC11 or speak with your
healthcare provider.
About ResMedAt ResMed (NYSE: RMD, ASX: RMD) we
pioneer innovative solutions that treat and keep people out of the
hospital, empowering them to live healthier, higher-quality lives.
Our digital health technologies and cloud-connected medical devices
transform care for people with sleep apnea, COPD, and other chronic
diseases. Our comprehensive out-of-hospital software platforms
support the professionals and caregivers who help people stay
healthy in the home or care setting of their choice. By enabling
better care, we improve quality of life, reduce the impact of
chronic disease, and lower costs for consumers and healthcare
systems in more than 140 countries. To learn more,
visit ResMed.com and follow @ResMed.
For
media +1
858.289.7272 news@resmed.com
For investors+1
858.836.5000investorrelations@resmed.com
1 ASV therapy is contraindicated in patients with chronic,
symptomatic heart failure (NYHA 2-4) with reduced left ventricular
ejection fraction (LVEF ≤ 45%) and moderate to severe predominant
central sleep apnea.
2 Malhotra A et al. "Patient Engagement Using New Technology to
Improve Adherence to Positive Airway Pressure Therapy" CHEST
2018
3 The myAir™ app is available in English and Spanish in the US
and in English and French in Canada. Some features of myAir™ are
only available in the myAir™ app and with Air11™ devices.
ResMed (NYSE:RMD)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
ResMed (NYSE:RMD)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024